Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 3: 478 - 488

DOI: https://doi.org/10.19852/j.cnki.jtcm.20240408.003

Original articles

Investigation of the active ingredients and mechanism of Shuangling extract in dextran sulfate sodium salt induced ulcerative colitis mice based on network pharmacology and experimental verification

  • Mengzhen CHU ,
  • Yu WANG ,
  • Zhijian LIN ,
  • Jintao Lyu ,
  • Xiaomeng ZHANG ,
  • Bing ZHANG
Expand
  • Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China

Received date: 2023-02-22

  Accepted date: 2023-06-15

  Online published: 2024-04-08

Supported by

Innovation Team and Talents Support Program of National Administration of Traditional Chinese Medicine: Construction and Practice of Pharmacovigilance Theory System in Line with the Characteristics of Traditional Chinese Medicine(ZYYCXTD-C-202005-11);National Leading Talents Support Plan of Traditional Chinese Medicine ‘Qihuang Scholar’ Plan: Chinese Medicine Inheritance and Innovation "One Hundred Million" Talent Project (Qihuang Project) Qihuang Scholars(1040063320004)

Fold

Abstract

OBJECTIVE: To explore the pharmacodynamic effects and potential mechanisms of Shuangling extract against ulcerative colitis (UC).

METHODS: The bioinformatics method was used to predict the active ingredients and action targets of Shuangling extract against UC in mice. And the biological experiments such as serum biochemical indexes and histopathological staining were used to verify the pharmacological effect and mechanism of Shuangling extract against UC in mice.

RESULTS: The Shuangling extract reduced the levels of seruminterleukin-1β (IL-1β), tumor necrosis factor-α (TNF-N), interleukin-6 (IL-6) and other inflammatory factors in UC mice and inhibited the inflammatory response. AKT Serine/threonine Kinase 1 and IL-6 may be the main targets of the anti-UC action of Shuangling extract, and the TNF signaling pathway, Forkhead box O signaling pathway and T-cell receptor signaling pathway may be the main signaling pathways.

CONCLUSION: The Shuangling extract could inhibit the inflammatory response induced by UC and regulate intestinal immune function through multiple targets and multiple channels, which provided a new option and theoretical basis for anti-UC.

Key words： colitis, ulcerative; pharmacodynamic study; network pharmacology; molecular docking simulation; Shuangling extract

Cite this article

Mengzhen CHU , Yu WANG , Zhijian LIN , Jintao Lyu , Xiaomeng ZHANG , Bing ZHANG . Investigation of the active ingredients and mechanism of Shuangling extract in dextran sulfate sodium salt induced ulcerative colitis mice based on network pharmacology and experimental verification[J]. Journal of Traditional Chinese Medicine, 2024 , 44(3) : 478 -488 . DOI: 10.19852/j.cnki.jtcm.20240408.003

References

1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017; 389: 1756-70.
2. Chen F, Yan CK. Recent progress in drug therapy of ulcerative colitis. Shi Jie Hua Ren Xiao Hua Za Zhi 2016; 24: 1840-45.
3. Zeng SM, Lin WH, Luo PJ, Wei J, Liang Q, Huang GH. Progress in Traditional Chinese Medicine treatment of ulcerative colitis. Liaoning Zhong Yi Za Zhi 2020; 47: 209-12.
4. Wang YZ, Gao S, Li LJ, Zhang L, Sun Y, Bao FM. Research advances on bioactivity and pharmacological effects of chicoric acid. Zhong Guo Xin Yao Za Zhi 2020; 29: 1729-33.
5. You X, Xiong DG, Guo ZB, Shang YJ. Advancement of a variety of chemical constituents and pharmacological mechanisms of poriacocos. Anhui Nong Ye Ke Xue 2015; 43: 106-9.
6. Wang XL, Peng YH, Sun MY, Shi Y. The knowledge of disease cause of Traditional Chinese Medicine to ulcerative colitis. Liaoning Zhong Yi Za Zhi 2007; 34: 572-3.
7. Fang WY, Zhong YB, Liu DY, Zhao HM. Progress in clinical research of Bupiyichang pill in treating ulcerative colitis. Jiangxi Zhong Yi Yao Da Xue Xue Bao 2021; 33: 116-20.
8. Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Chem Inform 2014; 6: 13.
9. Ahmed SS, Ramakrishnan V. Systems biological approach of molecular descriptors connectivity: optimal descriptors for oral bioavailability prediction. PLoS One 2012; 7: e40654.
10. Zong Y, Dong HL, Chen T, Yan S, Jiang GR. Mechanism of herb pair containing Scutellariae Radix and Coptidis Rhizoma on treatment of type 2 diabetes mellitus based on network pharmacology. Zhong Cao Yao 2019; 50: 888-94.
11. Daina A, Michielin O, Zoete V. Swiss Target Prediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 2019; 47: W357-64.
12. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019; 47: D506-15.
13. Amberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes. Curr Protoc Bioinformatics 2017; 58: 1.2. 1-12.
14. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018; 46: D1074-82.
15. Wang Y, Zhang S, Li F, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res 2020; 48: D1031-41.
16. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47: D607-13.
17. Jiao X, Sherman BT, Huang da W, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics 2012; 28: 1805-6.
18. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
19. Su M, Guo C, Liu M, Liang X, Yang B. Therapeutic targets of vitamin C on liver injury and associated biological mechanisms: a study of network pharmacology. Int Immunopharmacol 2019; 66: 383-7.
20. Du Z, Zhou X, Ling Y, Zhang Z, Su Z. AgriGO: a GO analysis toolkit for the agricultural community. Nucleic Acids Res 2010; 38: W64-70.
21. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017; 45: D353-61.
22. Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res 2021; 49: D1388-95.
23. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009; 30: 2785-91.
24. Adasme MF, Linnemann KL, Bolz SN, et al. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res 2021; 49: W530-4.
25. Kozlovskii I, Popov P. Spatiotemporal identification of druggable binding sites using deep learning. Commun Biol 2020; 3: 618.
26. Li AA, Jiang T, Zhan M, et al. Pharmacological mechanism of Shenling Baizhu San in the treatment of knee osteoarthritis based on network pharmacology and molecular docking. Zhong Guo Zu Zhi Gong Cheng Yan Jiu 2022; 26: 205-12.
27. Song X, Zhang Y, Dai E, Wang L, Du H. Prediction of triptolide targets in rheumatoid arthritis using network pharmacology and molecular docking. IntImmunopharmacol 2020; 80: 106179.
28. Jian GH, Su BZ, Zhou WJ, Xiong H. Application of network pharmacology and molecular docking to elucidate the potential mechanism of Eucommiaulmoides-Radix Achyranthis Bidentatae against osteoarthritis. Bio Data Min 2020; 13: 12.
29. Ye M, Luo G, Ye D, et al. Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen granules against coronavirus disease 2019 pneumonia. Phytomedicine 2021; 85: 153401.
30. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracoloniccyclosporin. Dig Dis Sci 1993; 38: 1722-34.
31. Bian M, Wang J, Wang Y, et al. Chicory ameliorates hyperuricemia via modulating gut microbiota and alleviating LPS/TLR4 axis in quail. Biomed Pharmacother 2020; 131: 110719.
32. Boirivant M, Fuss IJ, Ferroni L, De Pascale M, Strober W. Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis. J Immunol 2001; 166: 3522-32.
33. Yang J, Liu XX, Fan H, et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis. PLoS One 2015; 10: e0140551.
34. Liu P, Xu H, Shi Y, Deng L, Chen X. Potential molecular mechanisms of plantain in the treatment of gout and hyperuricemia based on network pharmacology. Evid Based Complement Alternat Med 2020; 2020: 3023127.
35. Liang J, Chen S, Chen J, et al. Therapeutic roles of polysaccharides from Dendrobium Officinaleon colitis and its underlying mechanisms. Carbohydr Polym 2018; 185: 159-68.
36. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
37. Peng MX, Xie HC. Research progress on regulating cytokines in the treatment of ulcerative colitis with Traditional Chinese Medicine and its effective ingredients. Hubei Min Zu Xue Yuan Xue Bao 2019; 36: 50-3.
38. Wen S, Zhong Z, He L, et al. Network pharmacology dissection of multiscale mechanisms for Jiaoqi powder in treating ulcerative colitis. J Ethnopharmacol 2021; 275: 114109.
39. Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. Ethanolic Garciniamangostana extract and α-mangostin improve dextran sulfate sodium-induced ulcerative colitis via the suppression of inflammatory and oxidative responses in ICR mice. J Ethnopharmacol 2021; 265: 113384.
40. Kou FS, Shi L, Li JX, et al. Clinical evaluation of Traditional Chinese Medicine on mild active ulcerative colitis: a multi-center, randomized, double-blind, controlled trial. Medicine (Baltimore) 2020; 99: e21903.
41. Ding P, Liu J, Li Q, et al. Investigation of the active ingredients and mechanism of Hudi enteric-coated capsules in DSS-induced ulcerative colitis mice based on network pharmacology and experimental verification. Drug Des Devel Ther 2021; 15: 4259-73.
42. Cui SX, Mao YF, Lu WM. Exploring the mechanism of Lianzhi Qingchang Tang in treating ulcerative colitis based on network pharmacology and molecular docking. Hunan Zhong Yi Za Zhi 2022; 38: 160-8.
43. Kim WS, Song HY, Han JM, Byun EB. GLM, a novel luteolin derivative, attenuates inflammatory responses in dendritic cells: therapeutic potential against ulcerative colitis. Biochem Biophys Res Commun 2019; 518: 87-93.
44. Bischoff TA, Kelley CJ, Karchesy Y, Laurantos M, Nguyen-Dinh P, Arefi AG. Antimalarial activity of lactucin and lactucopicrin: sesquiterpene lactones isolated from Cichoriumintybus L. J Ethnopharmacol 2004; 95: 455-7.
45. Zhang X, Lan D, Ning S, Ruan L. Anticancer action of lactucopicrin in SKMEL-5 human skin cancer cells is mediated via apoptosis induction, G2/M cell cycle arrest and downregulation of m = TOR/PI3K/AKT signalling pathway. J Buon 2018; 23: 224-8.
46. Venkatesan R, Shim WS, Yeo EJ, Kim SY. Lactucopicrin potentiates neuritogenesis and neurotrophic effects by regulating Ca2+/CaMKII/ATF1 signaling pathway. J Ethnopharmacol 2017; 198: 174-83.
47. Weso?owska A, Nikiforuk A, Michalska K, Kisiel W, Chojnacka-Wójcik E. Analgesic and sedative activities of lactucin and some lactucin-like guaianolides in mice. J Ethnopharmacol 2006; 107: 254-8.
48. He L, Weng H, Li Q, et al. Lactucopicrin inhibits cytoplasmic dynein-mediated NF-κB activation in inflammated macrophages and alleviates atherogenesis in apolipoprotein E-Deficient mice. Mol Nutr Food Res 2021; 65: e2000989.
49. Zhang N, Chen X. Potential role of O-GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitro. Biotechnol Appl Biochem 2016; 63: 841-51.
50. Zheng L, Wen XL, Dai YC. Mechanism of Jianpi Qingchang Huashi recipe in treating ulcerative colitis: a study based on network pharmacology and molecular docking. World J Clin Cases 2021; 9: 7653-70.
51. Hirano T. IL-6 in inflammation, autoimmunity and cancer. IntImmunol 2021; 33: 127-48.
52. Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. Tumour necrosis factor signalling in health and disease. F1000Res 2019; 8: F1000 Faculty Rev-111.
53. Kaisho T, Akira S. Toll-like receptors and their signaling mech-anism in innate immunity. Acta Odontol Scand 2001; 59: 124-30.
54. Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity 2019; 50: 992-1006.
55. Stucchi A, Reed K, O'Brien M, et al. A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis 2006; 12: 581-7.
56. Schwanke RC, Marcon R, Meotti FC, et al. Oral administration of the flavonoid myricitrin prevents dextran sulfate sodium-induced experimental colitis in mice through modulation of PI3K/Akt signaling pathway. Mol Nutr Food Res 2013; 57: 1938-49.
57. Baregamian N, Rychahou PG, Hawkins HK, Evers BM, Chung DH. Phosphatidylinositol 3-kinase pathway regulates hypoxia-inducible factor-1 to protect from intestinal injury during necrotizing enterocolitis. Surgery 2007; 142: 295-302.
58. Reddy SA, Huang JH, Liao WS. Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-kappa B activation. J Immunol 2000; 164: 1355-63.
59. Gustin JA, Ozes ON, Akca H, et al. Cell type-specific expression of the Ikappa B kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem 2004; 279: 1615-20.
60. Cook L, Stahl M, Han X, et al. Suppressive and gut-reparative functions of human type 1 T regulatory cells. Gastroenterology 2019; 157: 1584-98.
Options
Outlines

/

〈 〉